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Abstract
There is now effective therapy for infection by the Human Immunodeficiency Virus (HIV), but there
is no cure. Consequently, antiviral drugs must be administered continuously to suppress viral
replication. Recently, a large phase III international immune-based therapy trial was discontinued
because it is difficult to measure clinical endpoints while antivirals are administered. Since the
immune system has evolved under the selective force of microbial infections, the immune reaction
is antiviral. This commentary explores the rationale of using "Diagnostic Treatment Interruptions"
of antiviral therapies to determine efficacies of immune-based therapies.
Introduction
Recently, the Chiron Corporation announced the discon-
tinuation of an international phase III trial, which was de-
signed to determine whether high dose intermittent
interleukin-2 (IL2) therapy could improve on the clinical
outcome of standard antiviral therapy for individuals in-
fected with the Human Immunodeficiency Virus (HIV).
After several years and the enrollment of almost 2000 vol-
unteers in 18 countries, the company yielded to reality.
The primary endpoint of the study, i.e. the rate of progres-
sion to an AIDS-defining illness while receiving Highly
Active Anti-Retroviral Therapy (HAART), is only ~2%/year
[1]. Therefore, to improve upon such an already successful
outcome by the addition of an immune-based therapy (or
any kind of therapy for that matter) would require five
more years. It proved to be too expensive for the company
to pursue. How then will it be possible to determine effi-
cacy when testing immune-based therapies combined
with antiviral therapies, especially efficacy that is accepta-
ble to the Food and Drug Administration (FDA)?
Discussion
The FDA will approve an agent for the treatment of any
disease if it can be shown to meet one of three fundamen-
tal clinical outcome criteria: 1) It is curative in a disease or
curative for a fraction of those afflicted. 2) It can prolong
disease-free survival. 3) It can improve the quality of life
while the therapy is administered. In some diseases the
FDA will accept a "surrogate outcome" if it has been
shown that the surrogate measurement correlates with the
clinical outcome, which usually requires more time, and/
or the clinical outcome is associated with significant mor-
bidity or mortality. For example, in the treatment of per-
sistent infection with Hepatitis C Virus (HCV), it has been
shown that a disappearance of detectable plasma HCV
levels 6 months after the cessation of therapy correlates
with a lack of progression to decompensated liver disease
[2]. Since the progression to decompensated liver disease
generally takes years and even decades, and results in a fa-
tal prognostic outcome without a liver transplant, the FDA
has accepted the clearance of plasma HCV as a "surrogate"
for a clinical outcome.
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Similarly, in the treatment of HIV infection, the FDA has
accepted agents that can be shown to reduce the concen-
tration of circulating HIV, even for as short a time interval
as 6 months. Actually, all of the antiviral agents now on
the market have been approved by the FDA on the basis of
these criteria. It follows that these same criteria may be
useful to determine whether immune-based therapies are
effective in this and other chronic viral infections.
In this regard, it is important to note and to emphasize
that the immune response is antiviral. In fact, viral infections
have been largely responsible for the selection of the host
defenses that have evolved to protect us against pathogens
that invade and replicate within our cells. Thus, the exqui-
site efficiency of the host reaction to viral infections is at-
tributable to the innate and acquired immune systems
and the capacity of virus-reactive NK cells and T cells to
proliferate massively and to differentiate into killer cells
and cells capable of producing antiviral cytokines and
chemokines.
Moreover, it is also important to note and to emphasize
that the immune response to HIV infection is the same as
it is in other viral infections, such as HCV, or poliovirus,
measles virus, mumps virus, EB-virus etc. In addition, the
fundamental ways in which the immune system has of
recognizing and responding to the introduction of foreign
molecules is identical, whether the source of the foreign
molecules is a microbial infection, an allograft, an aller-
gen, an autoantigen, or a tumor antigen. It follows that
immune-based therapies that focus on promoting the
quantity and quality of the immune response should be
beneficial in the treatment of a range of diseases, especial-
ly persistent viral infections and cancer. Moreover, treat-
ments that diminish the quantity and quality of the
immune reaction should be beneficial in the treatment of
allergies, allograft recipients and autoimmune disorders.
Given these principles, what is the best way to determine
the efficacy of IBTs? In cancer therapy the paradigm of
treating for a finite interval followed by discontinuation
of therapy and monitoring for the relapse rate over time
has been a tried-and-true clinical trial design for decades.
As well, the same clinical trial design has been used suc-
cessfully in persistent infections by HCV. In this instance,
the standard approach is to administer the therapy for 48
weeks, then to discontinue therapy and monitor for de-
tectable plasma HCV concentrations 24 weeks after the
cessation of therapy. Studies have shown that the absence
of detectable plasma HCV that persists 6 months after the
cessation of therapy, which is termed a "sustained viral re-
sponse", indicates that the individual will remain virus-
free for an extended interval, i.e. years. Consequently,
these individuals are considered "cured".
With regard to persistent HCV infection, the sustained vi-
ral response rate to standard antiviral therapy, which con-
sists of pegylated interferon-alpha (PEG-IFN-α) and
Ribavirin is ~56% [3,4]. However, if the data are analyzed
according to the genotype type of HCV, those infected by
Genotype I, which accounts for ~75% of all of those indi-
viduals in the U.S., the response rates are lower. Moreover,
if one examines the results of standard therapy for those
individuals who are infected with Genotype I who present
initially with a high plasma virus concentration, i.e. > 2
million mol/mL or > 800,000 IU/mL, then the sustained
viral response rate is only ~40%. Since ~75% of those in-
dividuals infected by Genotype I also have a high plasma
virus concentration, more than 50% of individuals in the
U.S. have only a 1 in 2.5 chance for a cure.
Studies of individuals who have responded to standard
antiviral therapy for HCV have revealed that they have
readily detectable immune responses that are specific for
HCV [5]. For example, these individuals can be identified
by detectable antigen-specific lymphocyte proliferation
assays (LPA) or cytolytic T lymphocyte (CTL) assays, while
those who do not respond to standard antiviral therapy
do not have easily detectable immune reactivity specific
for HCV. Accordingly, this information leads to the hy-
pothesis that IBTs should synergize with standard antivi-
ral therapy and lead to higher sustained viral response
rates.
In this regard, because only ~40% of individuals with
Genotype I and a high plasma HCV concentration re-
spond to standard therapy, the determination of the effi-
cacy of the addition of an IBT to the standard antiviral
therapy should not require thousands of volunteers. As
well, because the clinical trial design of a "Diagnostic
Treatment Interruption" (DTI) is standard in this disease,
the determination of the efficacy of IBTs should not re-
quire many years. Instead, a trial should be accomplished
within a relatively short interval, i.e. 2–3 years.
The same logic can also be applied to clinical trial designs
in the treatment of HIV infection. At this time there is ef-
fective antiviral therapy for HIV, but still the disease can-
not be cured. Even though continuous antiviral therapy
for several years can lead to undetectable plasma HIV con-
centrations, as soon as the therapy is discontinued, plas-
ma HIV once again becomes detectable within just a few
weeks [6]. Therefore, this infectious disease is unusual, in
that most microbial infections for which we have effective
antimicrobial therapy can be cured. In many respects,
chronic infection with HIV resembles cancer. Often effec-
tive cancer chemotherapy, radiotherapy or surgery can re-
sult in the complete disappearance of detectable tumor
cells, yet upon cessation of therapy the cancer once again
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Accordingly, since antiviral therapy of HIV infection can-
not result in any "cures", now the primary question con-
fronting the field is how can one achieve a "cure", and
how can one determine whether a "cure" has been
achieved. In this regard, it is important to define what we
mean by "cure". Webster's Dictionary defines cure as "to
rectify an abnormal or undesirable condition, usually by means
of medicines". Therefore, we are not seeking to eradicate or
eliminate the offending organism. Rather, the goal would
be to prevent replication of any residual virus that persists
after antiviral therapy. Given the understanding that viral
infections are naturally combated by cell-mediated im-
munity (CMI), it follows that stimulation of the virus-spe-
cific CMI while suppressing viral replication with antiviral
drugs should be more effective than the antiviral drugs
alone.
A clinical trial design to rapidly and quantitatively meas-
ure the efficacy of an IBT is most important, given the ca-
pacity of the antiviral drugs to very effectively suppress
viral replication. The Chiron Corporation eventually real-
ized that it is difficult to assess efficacy using clinical end-
points while individuals continue to receive antiviral
drugs. Accordingly, given the knowledge that the immune
response is antiviral, the most logical measurement of the
efficacy of HIV immunity is the measurement of the virus
itself, in other words the "surrogate" endpoint. However,
it is difficult to quantify residual virus while individuals
continue to receive antiviral drugs. Several groups thought
that they had achieved elimination of all residual viral
particles as evidenced by the inability to detect viral RNA
or DNA in biopsies, only to observe rapid viral relapse
when the antivirals were discontinued [7,8].
We have found that using a clinical trial design that in-
cludes a DTI provides for a very rapid and quantitative
endpoint for testing IBTs [9,10]. As well, if the IBTs are ad-
ministered while antivirals suppress endogenous viral
replication maximally, then the immune system should
not be laboring under the influence of an ongoing ineffec-
tual immune response to a persistent viral infection. The
idea is to improve both the quantity and quality of the im-
munity to HIV before the antiviral drugs are withdrawn,
so that the immune system is better equipped to combat
viral replication when the antiviral drugs are no longer
present.
Because HIV resumes replication very rapidly upon inter-
ruption of antiviral therapy, it is not even necessary to
wait 6 months to determine whether there are any sus-
tained viral responders. The mean time to detectable plas-
ma HIV is ~2 1/2 weeks, and our experience is that all
individuals relapse within 6 weeks [9]. Therefore, by mon-
itoring plasma HIV concentration weekly, it is possible to
very accurate determine the characteristics of the viral re-
lapse just 12 weeks after the cessation of antiviral therapy.
In addition, because the determination of plasma HIV
concentration is very quantitative and sensitive (LLD = 50
molecules/mL), measurement of the "surrogate end-
point" is more accurate than measurement of a clinical
endpoint. Accordingly, this clinical trial design does not
require large numbers of subjects to identify promising
therapies. Instead, studies designed to involve < 100 sub-
jects can be powered sufficiently to determine efficacy.
These considerations are important when large phase III
HIV vaccine trials are contemplated, testing the efficacy of
potential prophylactic vaccines in areas of the world
where the incidence of infection is high. Such large place-
bo controlled trials will require thousands of volunteers
and many years to await natural infection. The costs and
complexities of conducting such large trials, especially in
third world countries that lack sufficient medical infra-
structure, are enormous. All of these considerations lead
to the proposal to first conduct therapeutic trials of im-
mune-based therapies and vaccines in the first world
where there are readily available clinical and research fa-
cilities, only moving to large phase III prophylactic trials
in the third world when a given vaccine and IBT is proved
therapeutically efficacious.
Conclusions
Several pharmaceutical firms, including Chiron, are devel-
oping HIV vaccines with the intention to test them as a
means of prophylaxis against this dread infection. In ad-
dition, some are proceeding to test their best vaccine can-
didates as therapeutics. It is important that these trials
move forward as rapidly as possible. For this to occur, the
community of scientists, physicians and HIV-infected in-
dividuals need to promote the concept that we all must
work together to participate in clinical trials designed to
work towards a cure for this viral infection. Without a con-
certed effort, it really will take decades to achieve a cure,
and even more decades to achieve prevention.
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